By the broad and profound effects on the expression of genes and markers of hematopoietic differentiation produced by Kaiso knock-down, these findings reveal Kaiso as a potential target for selective therapy of CML. This evidence concerns the gene ZBTB33 and chronic myelogenous leukemia, BCR-ABL1 positive.